Description:
Neurotrope Bioscience is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
For more information, visit: http://www.neurotrope.com/
Market Information (as of June 30, 2019):
Symbol: NTRP
Stock Price: $8.02
Market Cap: $104,123,251
Outstanding Shares: 12,982,949
Warrants:
Series A-E warrants (expires November 2020): - 819,914 warrants exercisable at $32.00 ($26,237,248)
- 147,606 warrants exercisable at $0.32 ($47,234)
Series F warrants (expires November 2021):
- 3,751,033 warrants exercisable at $12.80 ($48,013,222)
- 382,887 warrants exercisable at $6.40 ($2,450,477)
Series G warrants (expires June 2024):
- 5,001,677 warrants exercisable at $4.37 ($21,857,328)
- 100,240 warrants exercisable at $6.25 ($626,500)
Other warrants:
- 24,000 warrants exercisable at $7.12 ($170,880)
- 90,000 warrants exercisable at $7.13 ($641,700)
Options Outstanding (Weighted Average Exercise Price: $13.37): 2,295,246 ($30,687,439)
To be raised from exercised warrants & options: $133,027,274
Fully Diluted Shares (Outstanding Shares + Warrants + Options Outstanding): 25,595,552
Fully Diluted Market Cap: $205,276,327
Reports:
Roth report: https://pdfhost.io/v/i@2x9BB+F_37943455120180308NTRPRothInitpdf.pdf
Maxim report: https://pdfhost.io/v/agpp@2Q+o_379427337NTRPinitiationpdf.pdf
Janney report: https://pdfhost.io/v/iQV43NGcT_413879072NTRPInitiation06182019pdf.pdf
Press Releases:
Phase 2a results: https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-its-phase-2a-study-of-bryostatin-1-in-alzheimers-disease-300038367.html
Exploratory Phase 2b results: https://www.prnewswire.com/news-releases/neurotropes-bryostatin-improves-cognition-in-patients-with-advanced-alzheimers-disease-based-on-further-analysis-of-phase-2-clinical-trial-data-300578025.html
Scientific Articles:
[P2a & CU results] "Bryostatin Effects on Cognitive Function and PKC epsilon in Alzheimer’s Disease Phase IIa and Expanded Access Trials" (2017): https://pdfhost.io/v/XAcILs@Hc_jad2F20172F5822Fjad582jad1701612Fjad58jad170161pdf.pdf
[Exploratory P2b results] "A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Ef?cacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease" (2018): https://pdfhost.io/v/GEa58CPiF_farlow2018pdf.pdf
[Memantine results] "Memantine in Moderate-to-Severe Alzheimer's Disease" (2003): https://www.nejm.org/doi/full/10.1056/NEJMoa013128
More scientific articles: https://justpaste.it/58cm8
Patents:
Patents by Daniel L. Alkon: https://patents.justia.com/inventor/daniel-l-alkon
Patents by Daniel L. Alkon (grants only): http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&p=1&f=S&l=50&Query=IN%2FAlkon-Daniel-L.&d=PTXT
Patents by Daniel L. Alkon (applications only): http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=0&p=1&f=S&l=50&Query=IN%2FAlkon-Daniel-L&d=PG01
Media:
"A new era for treating diseases of the brain" (2008): https://youtu.be/W1pdg1kvQHI
"Rockefeller Institute drug provides hope for Alzheimer’s treatment" (2015): https://www.wvgazettemail.com/news/rockefeller-institute-drug-provides-hope-for-alzheimer-s-treatment/article_bf5bab5f-e40e-5f47-95ca-666f14b795e0.html
"The Scoop: Alzheimer’s Drug Tries to Build Up a Head of Steam" (2018): https://www.genengnews.com/magazine/the-scoop-alzheimers-drug-tries-to-build-up-a-head-of-steam/
"Advancements in Alzheimer’s Treatment: Interview with Dr. Daniel Alkon" (2018): https://newyork.legalexaminer.com/health/senior-care/advancements-in-alzheimers-treatment-interview-with-dr-daniel-alkon/
JPMorgan Alzheimer's Key Opinion Leader Call (2019): https://sndup.net/8rw4
Oppenheimer Alzheimer's Key Opinion Leader Call (2019): https://sndup.net/6pw6
"Company Seeks to Prove Marine-Derived Alzheimer's Drug Is No Fish Story" (2019): https://soundcloud.com/levine-media-group/company-seeks-to-prove-marine-derived-alzheimers-drug-is-no-fish-story
"Pizza Hut co-founder’s compassionate-care Alzheimer’s trial leads to hope for others" (2019): https://www.kansas.com/news/business/biz-columns-blogs/carrie-rengers/article229253744.html
"After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug" (2019): https://www.npr.org/sections/health-shots/2019/05/03/718754791/after-a-big-failure-scientists-and-patients-hunt-for-a-new-type-of-alzheimers-d
Dr. Alkon at Alzheimer's Solutions Conference (2019): https://www.youtube.com/watch?v=bP5GcAplXls
How an Alzheimer’s ‘cabal’ thwarted progress toward a cure (2019): https://www.scribd.com/document/414776750/Stat062519
Charles Ryan On Treating Alzheimer's Disease (2019): https://tdameritradenetwork.com/video/rB4AoWt8Hk2Ba5865CUHvQ
The Impacts of Alzheimer's Disease are Growing (2019): https://www.youtube.com/watch?v=x4NkJqASGZc
Ellis Martin Report with Neurotrope's Dr Daniel Alkon: Successfully Reversing Alzheimer's Disease? (2019): https://www.youtube.com/watch?v=KwkiUj2uGgA
Links:
Investor relations: http://www.neurotrope.com/ir/
Institutional ownership: https://www.nasdaq.com/symbol/ntrp/institutional-holdings
SEC filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001513856&owner=include&count=40&hidefilings=0
NTRP at Stocktwits: https://stocktwits.com/symbol/NTRP
NTRP at Investorvillage: https://www.investorvillage.com/smbd.asp?mb=19529
Bryostatin vs. Memantine vs. Placebo comparison: https://i.imgur.com/579PX0L.jpg
Test comparison: https://i.imgur.com/s61opUd.jpg